Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SAGE Therapeutics Inc SAGE

Healthcare Biotechnology
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of... see more

Recent & Breaking News (NDAQ:SAGE)

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

Business Wire December 1, 2021

Sage Therapeutics to Host Sage FutureCast Webcast

Business Wire November 29, 2021

Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Business Wire November 24, 2021

Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference

Business Wire November 11, 2021

Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

Business Wire November 2, 2021

Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

Business Wire October 20, 2021

Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022

Business Wire October 19, 2021

Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress

Business Wire October 4, 2021

Sage Therapeutics Launches SageCitizen Social Impact Initiative

Business Wire October 1, 2021

Sage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer

Business Wire September 21, 2021

Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington's Disease

Business Wire September 15, 2021

Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference

Business Wire September 2, 2021

Sage Therapeutics to Present at Upcoming August Investor Conferences

Business Wire August 4, 2021

Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

Business Wire August 3, 2021

Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

Business Wire July 20, 2021

Sage Therapeutics to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

Business Wire July 8, 2021

Sage Therapeutics to Participate in SVB Leerink's 3rd Annual CNS Forum

Business Wire June 24, 2021

Sage Therapeutics to Host Conference Call

Business Wire June 15, 2021

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

GlobeNewswire June 15, 2021

Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day

Business Wire May 20, 2021